Oeneo Valuation
Is O64 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of O64 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: O64 (€9.66) is trading above our estimate of fair value (€9.35)
Significantly Below Fair Value: O64 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for O64?
Key metric: As O64 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is O64's PE Ratio? | |
|---|---|
| PE Ratio | 22.1x |
| Earnings | €28.85m |
| Market Cap | €637.85m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.3x |
| Enterprise Value/EBITDA | 11.5x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does O64's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.2x | ||
ACT AlzChem Group | 12.2x | 12.6% | €586.2m |
STO3 Sto SE KGaA | 11x | 7.8% | €723.6m |
SIM0 SIMONA | 11.4x | n/a | €342.0m |
UZU Uzin Utz | 10.2x | 2.1% | €243.1m |
O64 Oeneo | 22.1x | 9.1% | €637.9m |
Price-To-Earnings vs Peers: O64 is expensive based on its Price-To-Earnings Ratio (22.1x) compared to the peer average (11.1x).
Price to Earnings Ratio vs Industry
How does O64's PE Ratio compare vs other companies in the European Packaging Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: O64 is expensive based on its Price-To-Earnings Ratio (22.1x) compared to the European Packaging industry average (17.7x).
Price to Earnings Ratio vs Fair Ratio
What is O64's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 22.1x |
| Fair PE Ratio | 12.2x |
Price-To-Earnings vs Fair Ratio: O64 is expensive based on its Price-To-Earnings Ratio (22.1x) compared to the estimated Fair Price-To-Earnings Ratio (12.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €9.62 | €12.27 +27.5% | 2.7% | €12.50 | €11.80 | n/a | 3 |
| Nov ’25 | €9.62 | €12.47 +29.6% | 1.6% | €12.70 | €12.20 | n/a | 3 |
| Oct ’25 | €9.76 | €12.47 +27.7% | 1.6% | €12.70 | €12.20 | n/a | 3 |
| Sep ’25 | €10.35 | €12.47 +20.5% | 1.6% | €12.70 | €12.20 | n/a | 3 |
| Aug ’25 | €10.20 | €12.47 +22.2% | 1.6% | €12.70 | €12.20 | n/a | 3 |
| Jul ’25 | €10.50 | €12.47 +18.7% | 1.6% | €12.70 | €12.20 | n/a | 3 |
| Jun ’25 | €11.65 | €12.40 +6.4% | 0.8% | €12.50 | €12.30 | n/a | 2 |
| May ’25 | €9.96 | €12.45 +25.0% | 0.4% | €12.50 | €12.40 | n/a | 2 |
| Apr ’25 | €9.24 | €12.87 +39.2% | 4.6% | €13.70 | €12.40 | n/a | 3 |
| Mar ’25 | €10.70 | €12.87 +20.2% | 4.6% | €13.70 | €12.40 | n/a | 3 |
| Feb ’25 | €11.60 | €12.87 +10.9% | 4.6% | €13.70 | €12.40 | n/a | 3 |
| Jan ’25 | €12.60 | €13.53 +7.4% | 3.4% | €14.00 | €12.90 | n/a | 3 |
| Dec ’24 | €13.20 | €13.57 +2.8% | 3.1% | €14.00 | €13.00 | n/a | 3 |
| Nov ’24 | €12.80 | €14.33 +12.0% | 5.8% | €15.50 | €13.70 | €9.62 | 3 |
| Oct ’24 | €13.85 | €14.33 +3.5% | 5.8% | €15.50 | €13.70 | €9.76 | 3 |
| Sep ’24 | €13.75 | €14.43 +5.0% | 5.3% | €15.50 | €13.80 | €10.35 | 3 |
| Aug ’24 | €13.50 | €14.43 +6.9% | 5.3% | €15.50 | €13.80 | €10.20 | 3 |
| Jul ’24 | €13.95 | €15.07 +8.0% | 2.2% | €15.50 | €14.70 | €10.50 | 3 |
| Jun ’24 | €14.00 | €15.07 +7.6% | 2.2% | €15.50 | €14.70 | €11.65 | 3 |
| May ’24 | €14.25 | €15.10 +6.0% | 2.6% | €15.50 | €14.70 | €9.96 | 2 |
| Apr ’24 | €13.70 | €15.10 +10.2% | 2.6% | €15.50 | €14.70 | €9.24 | 2 |
| Mar ’24 | €14.85 | €15.10 +1.7% | 2.6% | €15.50 | €14.70 | €10.70 | 2 |
| Feb ’24 | €14.15 | €15.10 +6.7% | 2.6% | €15.50 | €14.70 | €11.60 | 2 |
| Jan ’24 | €14.10 | €15.10 +7.1% | 2.6% | €15.50 | €14.70 | €12.60 | 2 |
| Dec ’23 | €13.65 | €15.10 +10.6% | 2.6% | €15.50 | €14.70 | €13.20 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Transcontinental
CA$1.4b
Engages in the flexible packaging business in Canada, the United States, Latin America, the United Kingdom, Australia, and New Zealand.
53L
CA$11.20
7D
-0.9%
1Y
54.5%
Central Asia Metals
UK£279.8m
Operates as a base metals producer.
9C3
UK£1.97
7D
3.1%
1Y
2.1%
African Rainbow Minerals
R31.5b
Through its subsidiaries, operates as a diversified mining and minerals company in South Africa and Switzerland.
EB9
R8.40
7D
-5.1%
1Y
0.6%